We examine expression across normal brain and cancers, evaluate survival associations, map the co-expression and interaction contexts, and ask whether loss of OPCML promotes aggressive phenotypes by releasing PI3K–AKT–mTOR signaling. The gene discussed is MTOR; the disease is cancer.